Biography
Dr. Michelle Perugini is an academic and health tech entrepreneur with extensive experience in healthcare and advanced AI technologies. Michelle is also a dedicated advisor to many start-ups, a member of numerous Government Committees, and an avid supporter of the AI and women’s health sectors globally. She has a PhD in Medicine and was a post-doctoral research fellow in Oncology for a decade. She has founded 2 global AI tech companies, the first of which was acquired by EY in 2015. Michelle is currently Co-Founder and CEO of Presagen, an AI healthcare company building The Social Network for Healthcare, with a focus in women’s health. Presagen’s first product Life Whisperer uses AI for embryo selection to improve pregnancy outcomes in IVF, and is being sold in IVF clinics globally.

Talk

Clinical Dx Showcase:
Presagen
Social networks breaking down data barriers to support AI for Women’s Healthcare: Case study in fertility

Social Net. Enables Scalable AI
Social networks can solve the data access and bias problem in women’s health.

Biography
Professor Baker is the inventor of the Dxcover Liquid Biopsy suite and is responsible for the technical and scientific strategy and direction of the company. He was awarded a prestigious fellowship straight after PhD to work at the Robert Koch Institute and Harvard Medical School. He followed this with periods at the Ministry of Defence and several academic institutions. He is a global leader in clinical spectroscopy who has been awarded Top 6 Best British Tech Pioneers (2020), Fellow of the Society of Applied Spectroscopy (2020), Top 40 under 40 analytical scientists (2018), RSC Harrison Meldola Memorial Prize (2017) and the Emerging Leader in Molecular Spectroscopy (2016) amongst others. He is committed to the translation of his inventions from the bench to the bedside for the benefit of patients and global health.

Talk

Clinical Dx Showcase:
Dxcover Ltd
A clinical stage medtech company whose aim is to be a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other disease to improve survival and quality of life

Spectroscopic Liquid Biopsy for Multi-Cancer Early Detection
We present a rapid, low cost spectroscopic liquid biopsy platform capable of detecting cancer early

Biography
Dr. Giuseppe Di Caro has over 12 years of leading the design and execution of translational research studies in oncology. He is currently Associate Director of Translational Research for Epic Sciences, acting as a scientific subject matter expert for oncology biomarkers in the breast and lung cancer therapeutic area and clinical development lead in liaison with academic KOLs and biopharma partners. Before that, he was a Research Project Leader (RPL) at Pfizer advancing immune-oncology large molecule programs. He led a large cross-functional team from discovery and Lead optimization to candidate selection and development. His academic tenure included a Ph.D. in Experimental Pathology at the University of Milan and a Postdoctoral fellowship at the University of California San Diego, Department of Pharmacology. He led several peer-reviewed scientific articles aimed to improve the classification of tumor heterogeneity in large datasets of cancer patients and demonstrated the role of various tumor-infiltrating immune cells as predictive biomarkers.

Clinical Dx Showcase:
Epic Sciences

Biography
As an Application Scientist at Twist Bioscience, Casey focuses on custom NGS project support, new product development, and training. He has ten years of in-depth industry experience in qPCR, Sanger sequencer, and NGS.

Talk

Clinical Dx Showcase:
Twist Bioscience
Twist Bioscience, a rapidly growing synthetic biology company, is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Leading the way in Target Enrichment Technology
Learn how Twist Bioscience is writing the future of cancer research with early cancer detection offerings.

Biography
Chris Dingman has over 24 years of experience in the healthcare industry. A top-performing, proven sales leader with extensive expertise in oncology molecular diagnostics and the pharmaceutical industries, Chris has a successful track record of developing and launching laboratory-developed tests by growing commercial and marketing capabilities. He has helped build top-tier, successful sales teams with a culture of putting patients and physicians first. Chris holds a BA in marketing (cum laude) from the University of Colorado, Boulder, and an MBA in global management.

Talk

Clinical Dx Showcase:
OncoHost
OncoHost has developed the PROphet® platform, a plasma-based, proprietary proteomic analysis tool that guides decision-making in the choice of first-line anti-PD-(L)1 treatment regimens for cancer patients, analyzes resistance mechanisms, and suggests potential treatment combinations to overcome this resistance.

Proteomic and AI analysis for late-stage lung cancer
Liquid-based proteomic test to inform first line anti-PD-1/PD-L1 lung treatment decisions

Biography
Dr. Catherine Schnabel brings over 20 years of scientific and leadership experience in the biomedical and molecular diagnostics industries. Prior to joining Nucleix, Cathy was the Chief Scientific Officer of Biotheranostics, where she led the development and translation of proprietary molecular signatures for breast cancer and metastatic disease, including incorporation of these novel technologies into clinical practice guidelines. An industry leader in evidencebased diagnostics, she has authored over 100 peerreviewed publications and disclosures and is an inventor on several patents. Cathy previously held research positions at Genentech, Genoptix and Amylin Pharmaceuticals, where she investigated and launched firstinclass therapies and biomarkers. Cathy holds a Ph.D. in cell and developmental biology from the Center for Advanced Biotechnology and Medicine at Rutgers University and was a fellow of the NIH and the Leukemia and Lymphoma Society at Stanford University.

Talk

Clinical Dx Showcase:
Nucleix
Nucleix is a liquid biopsy company revolutionizing early cancer detection and recurrence monitoring through its pioneering methylation based EpiCheck technology. Construction of its NGS Lung Cancer Atlas focused on stage I disease will provide a high-resolution platform to discover novel, multi-omic biomarkers for cancer screening.

Epigenetic Detection of Early-stage Lung Cancer
Advancing liquid biopsy tests to detect cancer earlier for better outcomes for patients.

Biography
Dan is the Chief Data Officer at InterVenn, with over 15 years of experience mining the genome and proteome for biological and clinical insights. After joining in late 2017, his team was responsible for training, deploying, and publishing the worlds first neural network for mass spectrometry peak selection and integration. Prior to starting at InterVenn, Dan led analytical efforts for dozens of scientific publications in cancer, neurodegenerative disease, and cardiovascular health at the Mayo Clinic. He holds a Bachelor of Science degree in Mathematics from the University of Minnesota and a Masters in Applied Statistics from Penn State. His team continues development on advanced machine-learning techniques for detecting, quantifying, and utilizing glycoproteins, in service of the ultimate goal: moving these novel biomarkers into clinical practice and improving patient outcomes.

Talk

Clinical Dx Showcase:
InterVenn Bioscience

Glycoproteomics: Next-Gen Biomarkers in Personalized Health Care
Recent advances in analytical technology, based on a combination of massspectrometry and artificial intelligence, have opened up a vast new territory of powerful biomarkers, orders of magnitude richer and more sensitive and specific than genomics and proteomics: posttranslational modification moieties of proteins, specifically glycosylation isoforms, as demonstrated by InterVenns data across a range of indications.

Biography
Sungwon Lim is a bioengineer/entrepreneur with 20 years of collective experience in academia, pharmaceutical companies, and biotech industries. He co-founded ImpriMed in 2017 with a strong motivation to innovate a way to help cancer patients who need an effective treatment “today”, by optimizing and personalizing drug treatment options currently available in our medical toolbox. ImpriMed builds comparative oncology platforms for precision medicine. The team first developed and validated new cell-based, functional precision medicine technologies and AI-based predictive models in the veterinary oncology space at a significantly higher speed with readily accessible clinical data. ImpriMed is now using the collected database and knowledge to apply to human oncology for the same cancer type. Dr. Lim received his Ph.D. in Bioengineering from Stanford University, M.S. in Translational Medicine at U.C. Berkeley and U.C. San Francisco, and B.S. in Chemical and Biomolecular Engineering at Korea Advanced Institute of Science and Technology.

Talk

Clinical Dx Showcase:
ImpriMed
ImpriMed provides an anticancer drug efficacy prediction service using artificial intelligence on a patient's live cancer cell data, aiming to help oncologists personalize a treatment regimen tailored to each patient's unique cancer in both human and veterinary oncology.

Reinventing precision medicine: from dogs to humans
ImpriMed’s comparative oncology platform enables new precision medicine services for both human and animal cancers.

Biography
Dr. Bredemeyer is a product leader at Pierian, creating valuable solutions for clinical genomic laboratories through the development and growth of Pierian’s LDT and IVD platforms. In collaboration with Pierian’s Knowledgebase and software teams, he has helped design an automated tertiary analysis and clinical interpretation system and partnered with biocurators to create curation processes and automation for medical device compliance. He previously led Pierian’s Customer Success team and worked with numerous customers to bring workflow and reporting solutions to clinical molecular laboratories. Dr. Bredemeyer holds a Ph.D. in Immunology from Washington University in St. Louis. He served in policy and finance roles at the NIH and at Massachusetts General Hospital research labs. Dr. Bredemeyer helped lead NGS-based clinical assay development and validation efforts at Washington University’s Genomics and Pathology Services laboratory, an early pioneer in clinical NGS testing.

Talk

Clinical Dx Showcase:
Pierian
Pierian is a partner in precision medicine, enabling clinicians and medical facilities to advance clinical genomics programs and modernize patient care.

Democratizing Clinical ’Omics Globally
Precision medicine will reach patients worldwide when physicians and laboratories form partnerships.

Biography
Marvin is the Co-Founder and Chief Science Officer at Quantum Insights, Inc. where he now focuses on the analysis of complex biological data. In his previous position as a theoretical physicist at the Stanford SLAC Laboratory, he co-invented the Dynamic Quantum Clustering method, and developed methods for understanding problems in both particle physics and condensed matter physics.

Talk

Clinical Dx Showcase:
Quantum Insights, In
Quantum Insights uses principles from quantum mechanics to identify diagnostic signatures and enable precision medicine.

Using Quantum Mechanics Physics for Signature Discovery
Quantum Insights shows how patterns of expression link cancers and treatments.

Biography
Padma has 15+ years of experience leading and transforming organizations with disruptive diagnostic technologies to revenue stage companies with market leading tests. She has successfully launched multiple diagnostics globally, as kits and CLIA services, driving test inclusion as standard-of-care with expertise in oncology and transplant monitoring markets. Prior to joining ChromaCode, Padma held key leadership roles at Affymetrix, Roche, Guardant Health, CellMax Life, and Oncocyte.

Talk

Clinical Dx Showcase:
ChromaCode
ChromaCode’s HDPCR technology enables any laboratory in the world the ability to offer high-value diagnostics for Oncology Dx, MRD, Blood-based Monitoring, NIPT, and Infectious Disease.

HDPCR: Empowering High-Value Diagnostics for All Labs
Empowering high-value diagnostics for all labs in Oncology, MRD, Blood-based Monitoring, NIPT, and Infectious Disease.

Biography
Seamus Kearney graduated from the Queens University of Belfast with an MSc in Engineering and immediately began his career in the medical devices industry, where he has spent the last 22 years in a variety of roles from development lead, project management, QA/RA and clinical operations. Seamus has worked with many of the global leaders in the in vitro diagnostics industry, including J&J, Roche Diagnostics and QIAGEN and founded ARC Regulatory in 2010 with the aim of supporting companies in the IVD sector through myriad global regulations for device development and clinical validation. Over the past 7 years, ARC has focused on the precision medicine sector, supporting pharma and their Dx partners in global compliance from vendor selection, due diligence, Dx regulations, GCP, study management and monitoring.

Talk

Clinical Dx Showcase:
ARC Regulatory
ARC Regulatory is a niche provider of global regulatory and clinical research solutions to the precision medicine and IVD industry. Our mission is to support companies, from the world’s top pharmaceutical and biotech leaders to medical start-ups with the ambition to improve patient care.

How IVDR is Impacting Precision Medicine Trials
With IVDR Date of Application already taken place, ARC plans to deliver a talk surrounding current regulations.

Biography
Dr. Alipanahi is a computational biologist and machine learning scientist with over a decade of industry experience. Prior to cofounding Exai and becoming its Chief Scientific Officer, Babak served in research positions at Google and 23andMe, and cofounded Deep Genomics. As a postdoctoral fellow at the University of Toronto, he won the universitys prestigious Invention of the Year award in 2016 for his research on using deep learning for modeling biological processes. Babak has a Ph.D. degree in computer science from the University of Waterloo in Canada, a masters degree in electrical engineering from the University of Tehran, and a bachelors degree in electrical engineering from Tehran Polytechnic in Iran.

Talk

Clinical Dx Showcase:
Exai
Exai Bio is a next-generation liquid biopsy company. The company's proprietary RNA and AI-based liquid biopsy platform delivers clinical insights into cancer biology.Its mission is to enable a world where cancer can be detected early, diagnosed accurately, and treated in a personalized way.

A novel oncRNA-based platform for liquid biopsy tests
OncRNAs enable a novel liquid biopsy strategy for early cancer detection and monitoring residual disease.

Biography
Jhana Hendrickx holds a master degree in bio-engineering, specializing in cell and gene biotechnology and applications for human health engineering, and a doctoral degree in biomedical sciences. Jhana joined Novosanis, a medical device company and subsidiary of OraSure Technologies Inc., in 2021. She’s in charge of scientific affairs, managing the Key Opinion Leader network, running Scientific Advisory Boards and engaging with our customers. Also, she is in charge of clinical affairs and runs the in-house clinical trials in infectious diseases and oncology and supports trials executed by lead Principal Investigators globally.

Talk

Clinical Dx Showcase:
Novosanis
Novosanis is a wholly owned subsidiary of OraSure Technologies Inc (NASDAQ: OSUR) and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology.

First-Void Urine As A Liquid Biopsy For Disease Monitoring
First-void urine as a non-invasive liquid biopsy for disease monitoring and diagnostics.

Biography
Nir is a Professor of Computer Science and of Life Sciences at the Hebrew University of Jerusalem. Prof. Friedman pioneered the use of probabilistic graphical models in reverse engineering of regulatory networks from high-throughput biological assays. In the last decade he shifted his focus to studying molecular mechanisms of transcription and chromatin by combination of novel high-throughput experiments and analysis. He examines these questions both in basic science context and in application to medical diagnosis and decision-making. Prof. Friedman has published more than 150 papers in peer-reviewed journals and conferences. He is the recipient of multiple awards, including the Michael Bruno Memorial Award (Yad Hanadiv), the Alexander von Humboldt Research Award, and three Advanced Researcher ERC grants. Prof. Friedman co-authored a widely used textbook on probabilistic graphical models.

Talk

Clinical Dx Showcase:
Hebrew University
Hebrew University: The largest and oldest research university in Israel. Senseera: Startup company developing liquid biopsy assay.

Cell-free chromatin liquid biopsy
cfChIP-seq is a new informative modality for liquid biopsy

Biography
Dr. Mithun Shah is a Consultant Medical Oncologist specialising in medical oncology and malignant haematology. Based in Ahmedabad (India), Dr. Mithun Shah works as a Consultant Medical Oncologist at Zydus Hospitals and Gujarat Research & Medical Institute.

Talk

Clinical Dx Showcase:
CanCertain Limited
CanCertain utilises advanced 3D cell culture techniques to recommend personalised cancer treatments. With a turnaround time of just 8 working days, the CanCertain personalised plan helps the patient begin the most effective cancer treatment quickly, thus increasing the chances of early recovery.

Clinical Experience in India
Dr Shah presents clinical utility of CanCertain in Patients with advanced stage cancer.

Biography
Matthew Pink has over 12 years of experience in the pharma and diagnostics industries. He leads the biopharma services division at Biodesix, Inc. He previously served as Director of Business Development at CSL Behring followed by U.S. Director of Research External Innovation. Matthew has a B.S. in Biology from the University of Wisconsin-Madison and a Ph.D. in Neuroscience from the University of Colorado.

Talk

Clinical Dx Showcase:
Biodesix, Inc.
Biodesix, Inc. provides end-to-end diagnostic services for biopharma partners, including biomarker discovery, assay design and development, fit-for-purpose regulatory strategies, clinical trial testing, commercialization, and companion diagnostic capabilities. For biopharmaceutical therapeutics in development, we uncover novel insights about tumor biology and patient immune response.

Blood-based multi-omics to guide IO treatment strategy
A case study on how Biodesix utilizes genomics and proteomics to identify patients for immunotherapy.

Biography
Chris Hall joined Personalis in October 2022 as Senior Vice President and Head, Diagnostics Business. As part of the executive leadership team, Hall drives the vision and strategy for commercializing the company’s diagnostic product offerings. Hall brings over 20 years of experience in general management and product development within the diagnostics industry, most recently as CEO of Naring Health, Inc. Previously, he served as President, COO, and Chief Commercial Officer at Veracyte, Inc., where he led the company’s commercial entry into endocrinology and pulmonology and scaled its operational groups. Hall also served as SVP and Chief Business Officer at Berkeley HeartLab, Inc. (part of Celera Corporation), where he helped a new product launch and restructured operations to improve profitability and streamline delivery of services. Hall holds a BA in political science and economics from DePauw University and an MBA from Harvard Business School.

Talk

Clinical Dx Showcase:
Personalis
Personalis is transforming the active management of cancer through more personalized testing. With industry-leading products combining tumor-and-normal profiling with proprietary algorithms, you can detect recurrence at the earliest timepoints, confidently select therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development.

It’s Personal: The NeXT Gen. of LBx
Personalis is redefining precision oncology through more personalized tumor-informed assays.

Biography
Sandrine Miller-Montgomery, Pharm.D., Ph.D, is the Co-founder, President and CEO of Micronoma, the first cancer-detection company utilizing signals from microbial nucleic acids, to empower clinicians to diagnose cancer at an early stage with minimally invasive, microbiome-driven liquid biopsy technology. Before co-founding Micronoma, she was executive director of UC San Diego’s Center for Microbiome Innovation (CMI), which she co-led with renowned microbiome researcher, Dr. Rob Knight. Sandrine established a world-class team focused on expanding industry and academic collaborations in the field of microbiome research that resulted in raising more than tens of millions of dollars of financial support through key partnerships toward application of this science to AI, diet and nutrition, aging, environment, human disease understanding and more. Sandrine has a talent for assembling efficient and successful teams around innovative products as shown by her work at Helixis, acquired by Illumina, and Mo Bio Labs acquired by QIAGEN.

Talk

Clinical Dx Showcase:
Micronoma
Micronoma is the first cancer-detection company utilizing minimally invasive, microbiome-driven liquid biopsy technology for early-stage cancer detection. Founded in 2019 by leaders in microbiome research, with results publication in major papers (Nature, Science, Cell...) the company is headquartered in San Diego, California.

Microbiome driven liquid biopsy for early stage cancer detection
Microbiome driven liquid biopsy is not a contamination artifact; it is a revolutionary find in the evolution of cancer diagnostics.

Biography
Sivan Bercovici is the Chief Technology Officer at Karius, where he leads the computational and data efforts aimed at unlocking the clinical value in the microbiome data. Throughout his career, Sivan has developed novel machine-learning methods and analytical platforms that address broad challenges in genetics and the study of human disease. Prior to Karius, Sivan was a co-founder and Chief Technology Officer at Lifecode. He obtained his Ph.D. in Computer Science from Technion - Israel Institute of Technology and completed his postdoctoral research at Stanford University, as part of Stanford’s Artificial Intelligence Laboratory.

Talk

Clinical Dx Showcase:
Karius
Karius sees a world where infectious disease is no longer a major threat to human health. With the Karius Test®, we deliver unprecedented diagnostic insight to enable physicians to make rapid treatment decisions.

Liquid biopsy into the microbial world
Microbial cfDNA: Novel chemistries, data, and ML provide unprecedented and unbiased access to unique microbial profiles.

Biography
With over twenty years of experience in oncology, liquid biopsy, and molecular diagnostics, Dr. Wang will bring his expertise in clinical research, product development, and management to BioFluidica in 2022. As Vice President of Translational Medicine at BioFluidica, he drives and manages disease initiatives and clinical applications. Before joining BioFluidica, Dr. Wang served as the Vice President of Informatics at Mindera Health, Senior Director of Translational Research at Epic Sciences, and Director of Bioinformatics at AltheaDx, where he led the development of multiple clinical tests, genomics analysis pipelines, and machine learning algorithms. Mr. Wang has over 60 peerreviewed publications in journals, including sciences, PNAS, Blood and Cancer Research, etc. He earned an M.D. and Ph.D. from Jilin University and a certificate in business management.

Talk

Clinical Dx Showcase:
Biofluidica
BioFluidica innovates technology and processes to overcome the technical challenges that hinder the clinical application of liquid biopsy. BioFluidica created LiquidScan™ as an automated system for isolating and enriching circulating rare cells and exosomes from liquid biopsy samples and developed clinical molecular tests.

Accelerating Development of Liquid Biopsy Clinical Applications
LiquidScan, a rare cell and exosome enrichment system, has been adopted for various clinical applications.

Biography
Marija Plodinec co-founded ARTIDIS AG and in November 2017 became the CEO and a Member of the Board of Directors. She studied physics in Zagreb and received her doctorate in 2010 from the University of Basel. For twelve years, she has driven the development of ARTIDIS, a medical device for fast and early diagnosis of breast cancer based on a unique nanomechanical biomarker, bringing the technology from basic research to the first clinical studies. Marija Plodinec is a recognized expert in the field of physical sciences in oncology and has co-authored important scientific papers and patents in this field. She is also a member of several international organizations focusing on cancer research and its clinical applications. Under her leadership, ARTIDIS fundraised more than 35M USD, successfully completed the large clinical study on 545 patients in Switzerland, grew to +45 FTE and partnered up with leading US pharmaceutical and clinical institutions.

Talk

Clinical Dx Showcase:
ARTIDIS, AG
ARTIDIS AG is a clinical stage medical technology company developing the first nanotechnology platform for tissue analysis combined with a digital data platform intended for broad use in drug discovery, tissue engineering as well as for rapid diagnostics and personalized treatment optimization.

Changing the paradigm of tissue analysis
ARTIDIS: Changing the paradigm of tissue analysis and delivering personalized patient treatment strategies with nanotechnology.

Biography
Sandra Jernström holds a PhD in cancer genetics from the University of Oslo, where she together with her colleagues integrated different omics data from a breast cancer cohort to better stratify the patients. She has expertise in high-throughput drug and siRNA screening of 2D and 3D cell culture models, where she explored the difference in drug resistance mechanisms seen between the culture models. Before joining Okomera, she worked as a postdoc at Karolinska Institute in Sweden, with the aim to develop a method to perform drug screening directly on patient biopsies in 3D, to be able to guide the treatment. For this project she won a significant research grant competition at the SLUSH conference in Finland in 2018. In 2020, she joined Okomera, where she leads the bio application team and is in charge of clinical partnerships to gain clinical validation of the technology.

Talk

Clinical Dx Showcase:
Okomera
Okomera has developed a technology for screening cancer biopsies in order to select the best treatment for each patient.

Precision Cancer Medicine on a chip
Functional screening for drug efficacy assessment using 3D microtumors derived from cancer biopsies.

Biography
George Cardoza joined AccuraGen following a 12+ year tenure at NeoGenomics Laboratories where he served as Chief Financial Officer (CFO) from 20092018; President, Pharma Services Division from 20182021; and as President and Chief Operating Officer (COO), Lab Operations from 20212022. Earlier in his career Cardoza served as CFO at Protocol Integrated Direct Marketing and several positions at Quest Diagnostics including Controller, Central Region. George earned his Bachelors Degree in Finance and Accounting from Syracuse University and his M.B.A. in Management from Michigan State University Eli Broad College of Business.

Talk

Clinical Dx Showcase:
AccuraGen
AccuraGen aims to revolutionize cancer management through technology innovation in molecular testing. AccuraGen focuses on the analysis of highly fragmented circulating nucleic acid in blood and has developed proprietary technologies enabling superior performance in the analysis of genomic, epigenetic, and RNA changes.

Company Introduction and Leading Liquid Biopsy Platform
A unique liquid biopsy platform that offers best-in-class early cancer detection solution

Biography
Dr. Goldner is a molecular biologist and entrepreneur focused on defeating cancer due to a personal connection. He harnesses evolution to map the cancer resistome, which enables the discovery and development of smarter cancer therapies and diagnostics.

Talk

Clinical Dx Showcase:
Resistance Bio
resistanceBio has developed the ResCu system, a proprietary cancer culture system that predicts resistance mechanisms to novel and existing therapies often not seen until the clinic. When paired with our proprietary algorithm, ResistanceRank, we can identify and rank the importance of resistance mechanisms to identify patients with the highest likelihood of treatment success to a given therapy.

Capturing Cancers Adaptive Resistance Profiles Via the ResSu System
resistanceBio has developed a novel method and algorithm for picking up resistance mechanisms.

Biography
My research is focused on developing bioinformatics methods to understand the genetic basis of diseases and especially cancer. I have a broad background in genomics, with specific training and expertise in developing computational methods to understand the genetic basis of how cancers initiate, progress and evolve. I currently develop clinically validated genomic tests for Childrens Hospital Los Angeles.

Talk

Clinical Dx Showcase:
Children's Hospital LA
Children’s Hospital Los Angeles is one of the nation’s leading pediatric hospitals. True to our mission, we have been creating hope and building healthier futures since 1901. We deliver a level of care that’s consistently recognized as some of the best in the world.

Clinical utility of liquid biopsy assays in pediatric cancers
Clinical utility of liquid biopsy assays in pediatric cancers

Biography
With over 20 years of software development and leadership experience, Ian leads the technical innovation at GenomOncology. Ian created GenomOncology’s Precision Oncology Platform, and continues to innovate on the platform and GO solution offerings to ensure our precision oncology solutions best serve users.

Talk

Clinical Dx Showcase:
GenomOncology
GenomOncology is a precision oncology software company.GenomOncology's precision oncology solutions provide the healthcare community with technology and knowledge to drive actionable insights and ultimately advance cancer care.

Advancing Cancer Care with GenomOncology
Learn how GenomOncology's solutions provide the healthcare community with data-driven insights to improve cancer care.

Biography
Brian Hashemi is cofounder and Executive Chairman of Novigenix. A former NASA Principal Investigator and Researcher, Dr. Hashemi has extensive background in healthcare technology development and commercialization and has been an Assistant Professor at Baylor College of Medicine where he began his affiliation in the National Space Biomedical Research Institute. Brian holds a Ph.D. in Applied Physics from Cornell University in New York, and an MBA in Entrepreneurship from the Wharton School in Philadelphia

Clinical Dx Showcase:
Novigenix SA
Novigenix is a precision oncology biotech with a proprietary platform LITOseek optimized for mapping the response of the immune system to onset and progression of disease to provide actionable insights and precision solutions for optimization of patient’s therapeutic journey.

Next-Generation Immune-Based Liquid Biopsy Solutions
Liquid biopsy interrogation of the host immune response for early detection of cancer and immunotherapy optimization.

Biography
Experienced R&D Executive with a demonstrated history of working in the biotechnology industry. Specialized expertise in circulating cell free DNA, epigenetics and oncology including assay, application and technology design and development. Lead development and innovation for worlds first cell free noninvasive prenatal test (NIPT). Earned Doctor of Medicine degree (MD) from the Universität Hamburg.

Talk

Clinical Dx Showcase:
Juno DX
Juno Diagnostics™ is a health company bringing prenatal health information to patients by combining accessibility, affordability, and transparency. Juno Hazel™, is a non-invasive prenatal screening test that utilizes a proprietary Sample Collection Kit and improves access to testing without the high cost and phlebotomy requirements.

Enabling accessible and affordable prenatal testing
Juno™ is a health company bringing prenatal health information to patients by combining accessibility, affordability, and transparency.

Biography
Atul cofounded CellMax Life in 2012, with the singular goal of developing globally affordable and quantitative bloodtests for Early Cancer Detection. He was motivated to start CellMax as two members of his family had been diagnosed with cancer one of them was diagnosed with breast cancer within two weeks of receiving a conclusively negative mammogram. Atul has experience as a serial entrepreneur, CEO and angel investor. Previously he was also resident at MohrDavidow Ventures and Artiman Ventures. He specializes in identifying unmet market needs and matching them with earlystage technologies to achieve dramatically better results than prevailing standards. He has done that successfully multiple times.

Talk

Clinical Dx Showcase:
CellMax Life
CellMax Life is developing blood tests for cancer screening. FirstSight is the first and only blood-test for preventive cancer screening that has also received Breakthrough designation from the FDA.

Blood-Test for Preventive Colon Cancer Screening
Blood Test for Colon Cancer Preventive Screening.

Biography
Precia Group is a CRO co-founded by Donna Russell in 2020 to expand the number of women in research studies, especially in early phases. The company is focused on women’s reproductive health and pregnancy but will expand its service areas to include all aspects of women’s health across the lifespan. Prior to Precia Group, Russell worked in maternal health research, in the US as a Director of Research at Seattle Children’s Research Institute and globally, consulting with the Bill & Melinda Gates Foundation and other funders. She has extensive experience establishing biobanks to support pregnancy cohorts and research networks in the community-setting; and harmonizing collections across multiple networks to enable large-scale omics studies. She also serves on the board of a large community hospital affiliated with the University of Washington and has a deep understanding of how to successfully integrate research into the clinical setting to ensure high-quality, diverse, equitable studies.

Clinical Dx Showcase:
Precia Group

Biography
Dr. Young Seok Ju is the co-founder at Genome Insight. He leads the bioinformatics team at Genome Insight and also runs JuLab, a cancer genomics laboratory at KAIST (Korea Advanced Institute of Science and Technology), bringing years of experience and insight in whole-genome sequencing. He was a postdoctoral fellow at Wellcome Sanger Institute (Cambridge, UK) and currently also holds a faculty position as Associate Professor of the Graduate School of Medical Sciences and Engineering at KAIST. He received the Human Genome Organization’s (HUGO) Chen Award of Excellence in 2020, and received his MD and PhD from Seoul National University.

Talk

Clinical Dx Showcase:
Genome Insight
Genome Insight is a fast-growing whole-genome diagnostic and precision medicine company focusing on cancer and rare diseases. It has an automated whole-genome pipeline coupled with a bioinformatics-powered digital solution that rapidly generates meaningful medical insights making it possible to use them in real-life clinical settings.

Realizing precision medicine with whole-genome bioinformatics
Genome Insight's comprehensive cancer diagnostics solutions and its clinical utilities

Biography
Dr. Marica Grskovic has spent the past two decades building and leading high-performing technology and product development teams across transplant and cell therapy diagnostics. At CareDx, Dr. Grskovic is accountable for strategy and operational oversight of the Testing Services. Prior to CareDx, Dr. Grskovic was a founding scientist at the stem cell-based drug discovery platform technology company iPierian (acquired by BMS), and its spin out True North Therapeutics (acquired by Bioverativ). Dr. Grskovic completed her post-doctoral fellowship on gene regulation in stem cells at University of California San Francisco (UCSF) and holds a PhD in Molecular Biology and Biochemistry from European Molecular Biology Laboratory (EMBL) and University of Heidelberg, Germany.

Clinical Dx Showcase:
CareDx
CareDx is a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the transplant patient journey.